z-logo
Premium
Bacterial vaccines in chronic obstructive pulmonary disease: effects on clinical outcomes and cytokine levels
Author(s) -
Ruso Salvador,
Marco Francisco M.,
MartínezCarbonell Juan A.,
Carratalá José A.
Publication year - 2015
Publication title -
apmis
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.909
H-Index - 88
eISSN - 1600-0463
pISSN - 0903-4641
DOI - 10.1111/apm.12386
Subject(s) - medicine , copd , exacerbation , bronchiectasis , cytokine , immunology , pathogenesis , inflammation , lung , disease , gastroenterology
Chronic obstructive pulmonary disease ( COPD ) is a major cause of mortality and morbidity worldwide. Exacerbation episodes impair lung function leading to disease progression. Levels of inflammation markers correlate with disease severity. Bacterial immunomodulators have shown a beneficial effect in COPD , improving symptoms and reducing the rate of exacerbations. This is an observational prospective study on 30 patients diagnosed with bronchiectasis and COPD , who received bacterial autogenous vaccine for 12 months. The rate of exacerbation, severity of symptoms and lung function were studied at baseline and after treatment. In addition, plasma levels CRP , IL 6, IL 8, and TNF α were measured. After treatment we found a reduction in mean acute respiratory infections and signs of lung disease. Acute phase proteins IL 6 and CRP increased in blood and IL 8 decreased. These changes may be related to the repeated injection of inactivated bacteria. Given the implication of these factors in the pathogenesis of COPD , particularly the production of IL 8, the causes and consequences of cytokine modulation by bacterial vaccines should be investigated. Vaccination with autogenous vaccines for 1 year can produce a significant clinical improvement in COPD patients, reducing the frequency of exacerbations associated to changes in the profile of markers of inflammation.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here